– USA, CA – Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced the appointment of Dr. Lorence Kim (M.D) to its board as an independent director.
“Lorence is a highly-respected leader within the biotech industry and we are very pleased to bring his strategic, financial, and operational expertise to our board as we progress our mission to defeat RAS-addicted cancers,” said CEO and Chairman, Dr. Mark Goldsmith. “Revolution Medicines is certain to benefit from Lorence’s insights and perspective, as we continue to mature our rich development pipeline of groundbreaking, targeted cancer therapies.”
About Dr. Lorence Kim
Dr. Kim has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies.
Dr. Kim is known particularly for his time as CFO of Moderna, Inc., where over six years he was instrumental in raising $4.4 billion in capital to support the company’s platform efforts in mRNA therapeutics and the development of its pipeline of more than 20 drug candidates spanning oncology and other therapeutic areas. Before joining Moderna, Dr. Kim had a highly productive 14-year career at Goldman Sachs, where he advised numerous companies as a managing director and co-head of biotechnology investment banking.
Dr. Kim said, “This is a transformational time for Revolution Medicines as the company has begun advancing a series of highly original RAS(ON) Inhibitors into the clinic while continuing clinical development of promising RAS Companion Inhibitors. I am excited to join this talented board and look forward to collaborating with fellow directors and management to sustain the company’s strong momentum toward extraordinary new treatments for cancer patients.”
Dr. Kim currently serves on the boards of directors of Cowen, Inc., Flare Therapeutics, Inc., and Abata Therapeutics, Inc., and is a venture partner at Third Rock Ventures. He is also on the Board of Governors of the American Red Cross.
Dr. Kim received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. in healthcare management from the Wharton School of the University of Pennsylvania, and an A.B. in biochemical sciences from Harvard University.
About Revolution Medicines, Inc.
Revolution Medicines is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) Inhibitors designed to suppress diverse oncogenic variants of RAS proteins, and RAS Companion Inhibitors for use in combination treatment strategies. The company’s RAS(ON) Inhibitor RMC-6236 (RASMULTI) is in clinical development. Additional RAS(ON) Inhibitors in development include RMC-6291 (KRASG12C), RMC-9805 (KRASG12D) and RMC-8839 (KRASG13C), and a pipeline of research compounds targeting additional RAS variants. RAS Companion Inhibitors in clinical development include RMC-4630 (SHP2) and RMC-5552 (mTORC1/4EBP1).
Amgen’s abstract (“OA03.03”) at the 2022 World Conference on Lung Cancer is entitled “Sotorasib in Combination with RMC-4630, a SHP2 Inhibitor, in KRAS p.G12C-Mutated NSCLC and Other Solid Tumors.” It can be accessed on the conference website under the session OA03 – Molecular Targeted Treatments.
Revolution Medicines and Sanofi are sponsoring RMC-4630-03 as a complement to the CodeBreaK 101c trial under their global partnership on SHP2.
For more information: https://www.revmed.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.